Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06981234

Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial

Led by University of California, San Diego · Updated on 2025-06-17

25

Participants Needed

1

Research Sites

145 weeks

Total Duration

On this page

Sponsors

U

University of California, San Diego

Lead Sponsor

B

Breakthrough T1D

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this study is to learn about the effect of the study drug acetazolamide in individuals with Type 1 Diabetes. Specifically, whether acetazolamide provides benefits to the kidneys while minimizing any side effects of the drug. These changes will be measured by laboratory tests that tell us how well the kidneys are functioning.

CONDITIONS

Official Title

Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males and females 18 years or older at the time of consent
  • Individuals able to become pregnant must be at least 1 year post-menopausal or surgically sterile, or agree to use two contraception methods during the study
  • Individuals able to cause pregnancy must agree to use clinically acceptable contraception during the study
  • Clinical diagnosis of Type 1 Diabetes with stable medication regimen for at least 3 months
  • Estimated glomerular filtration rate (eGFR) of 45 ml/min/1.73m2 or higher
  • Serum bicarbonate level of 24 meq/L or higher
  • Negative urine toxicology screen
  • Able to provide written informed consent approved by an Institutional Review Board (IRB)
Not Eligible

You will not qualify if you...

  • History of allergic reaction to acetazolamide, other carbonic anhydrase inhibitors, or inactive ingredients in the tablets
  • Liver disease including cirrhosis or high liver enzyme levels
  • Hemoglobin A1c greater than 10.0%
  • Hemoglobin concentration less than 8 g/dL
  • Use of more than 4 anti-hypertensive medications or systolic blood pressure above 160 mm Hg at screening
  • Use of loop, thiazide, or potassium-sparing diuretics
  • Medical conditions requiring urgent surgical or medical intervention such as active cardiac or pulmonary issues, ongoing ischemia, uncorrected coronary artery disease, or heart failure
  • Institutionalized individuals like prisoners, those with significant mental illness, or nursing home residents
  • Active pregnancy, breastfeeding, or planning pregnancy during the study
  • Current participation in another clinical trial (observational studies excluded)
  • Inability to adhere to study regimen or comply with recommendations
  • Inability or unwillingness to travel to study visits

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UC San Diego Altman Clinical & Translational Research Institute

La Jolla, California, United States, 92037

Actively Recruiting

Loading map...

Research Team

T

Todd May, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here